diagnosis of hcv-cv
Item
diagnosis of hcv-cv: must have all of the following
boolean
C0019196 (UMLS CUI [1])
hcv rna- or seropositive
Item
hcv infection documented by serology and/or plasma hcv rna.
boolean
C1269695 (UMLS CUI [1])
C0855842 (UMLS CUI [2])
active vasculitis
Item
one or more organ system with objective evidence of active vasculitis such as:
boolean
C0042384 (UMLS CUI [1])
palpable purpura
Item
palpable purpura
boolean
C0151190 (UMLS CUI [1])
glomerulonephritis
Item
glomerulonephritis (defined by the presence of glomerular hematuria and/or new or worsening proteinuria);
boolean
C0017658 (UMLS CUI [1])
acute peripheral neuropathy
Item
acute peripheral neuropathy.
boolean
C0031117 (UMLS CUI [1])
detectable cryoglobulins or rheumatoid factors
Item
detectable cryoglobulins and/or rf.
boolean
C0392385 (UMLS CUI [1])
C0151379 (UMLS CUI [2])
cytostatic treatment failure
Item
failure of treatment with ifn-alpha and ribavirin to control manifestations of hcv-cv or intolerance to ifn-alpha/ribavirin regimen.
boolean
C0162643 (UMLS CUI [1,1])
C0002199 (UMLS CUI [1,2])
C0162643 (UMLS CUI [2,1])
C0035525 (UMLS CUI [2,2])
personal physician
Item
patients must have a personal physician responsible for the care of their hcv.
boolean
age
Item
ages of 18 and 75 years
boolean
C0001779 (UMLS CUI [1])
contraceptive methods
Item
willingness to use effective contraception during and for 12 months following rituximab treatment. effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or hormonal contraception.
boolean
C0700589 (UMLS CUI [1])
immunosuppressive therapy
Item
recent (within 4 weeks) initiation of or increase in immunosuppressive therapy.
boolean
C0021079 (UMLS CUI [1])
active systemic infection
Item
active systemic infection (other than hepatitis c).
boolean
C0009450 (UMLS CUI [1])
pregnancy or breast feeding
Item
pregnancy or breast feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
prior treatment with rituximab
Item
prior treatment with rituximab.
boolean
C1514463 (UMLS CUI [1,1])
C0393022 (UMLS CUI [1,2])
allergy to murine proteins
Item
known allergy to murine proteins.
boolean
C0020517 (UMLS CUI [1,1])
C1699668 (UMLS CUI [1,2])
renal insufficiency
Item
significant renal insufficiency (creatinine clearance less than 30 ml/min).
boolean
C1565489 (UMLS CUI [1])
life-threatening hcv-cv
Item
presence of life-threatening hcv-cv; defined as rapidly progressive glomerulonephritis (defined as a doubling of the serum creatinine over a 3 month period), cns vasculitis, cardiac disease due to active vasculitis, or gi vasculitis (defined by ischemic bowel, perforation, or infarction).
boolean
C0221239 (UMLS CUI [1])
C0042384 (UMLS CUI [2])
C0856069 (UMLS CUI [3])
hepatic insufficiency
Item
significant hepatic insufficiency as manifested by child-pugh classification of b or c.
boolean
C1306571 (UMLS CUI [1,1])
C2347612 (UMLS CUI [1,2])
variceal bleeding or encephalopathy
Item
history of variceal bleeding, encephalopathy.
boolean
C1739112 (UMLS CUI [1])
C0085584 (UMLS CUI [2])
history of liver transplantation.
Item
history of liver transplantation.
boolean
C0262926 (UMLS CUI [1,1])
C0023911 (UMLS CUI [1,2])
co-infection with either hbv or hiv
Item
co-infection with either hbv or hiv.
boolean
C2242656 (UMLS CUI [1])
C4062778 (UMLS CUI [2])
any condition compromising study protocol compliance
Item
any underlying medical condition that in the judgment of the investigator would put the patient at increased risk for serious infusion-related adverse events.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])